Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A syndromic intellectual disability disorder that is characterized by significant neurodevelopmental disabilities with limited to absent speech, behavioral issues, and craniofacial anomalies. Most distinctive features are neurodevelopmental with invariably severely limited speech, cleft or high arched palate, dental anomalies (crowding, macrodontia, abnormal shape), and behavioral issues with or without bone or brain anomalies.
No HPO annotations are available for this condition.
Age of onset: adulthood, childhood.
SATB2-associated syndrome (SAS) is a multisystem disorder characterized by significant neurodevelopmental compromise with limited or absent speech, behavioral issues, and craniofacial anomalies. To date, more than 500 individuals have been identified with a pathogenic variant in SATB2 [, , , , ]. The following description of the phenotypic features associated with this condition is based on these reports. Table 2. SATB2-Associated Syndrome: Frequency of Select Features
No formal clinical diagnostic criteria have been established for SATB2-associated syndrome (SAS).
SAS should be suspected in individuals with the following clinical and family history findings.
Clinical findings
Typically moderate-to-profound developmental delay or intellectual disability, including severe speech delay and, in some, absence of speech; however, individuals with milder developmental delay affecting predominantly speech have been reported.
No approved treatments are currently available for SATB2 associated disorder. The disease remains an area of unmet medical need.
No consensus clinical practice guidelines for SATB2-associated syndrome (SAS) have been published. Some broad recommendations have been published , and dedicated neurologic and skeletal surveillance recommendations have been proposed based on two large cohort studies . In the absence of published consensus guidelines, the following recommendations are based on the authors' personal experience managing individuals with this disorder.
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 6. SATB2-Associated Syndrome: Recommended Surveillance
No clinical trials have been registered for SATB2 associated disorder.
62 publications have been identified in PubMed for SATB2 associated disorder. Research spans Basic Science / Preclinical (37%), Case Report / Case Series (24%), and Review / Meta-Analysis (16%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 23 | 37% |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 1:11 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about SATB2 associated disorder
Finding | % of Affected Persons1 | Comment |
|---|---|---|
Developmental delay/ intellectual disability | 100% | Most commonly in the moderate-to-profound range |
Speech delay | 100% | — |
Craniofacial dysmorphism | 84% | — |
Dental anomalies | 98% | — |
Behavioral issues | 55% | — |
Elevated alkaline phosphatase | 62% | — |
Cleft palate | 45% | — |
Abnormal neuroimaging | 68% | — |
Micrognathia | 42% | — |
Hypotonia | 59% | — |
Feeding difficulties | 68% | — |
Low weight | 22% | — |
Low bone density | 26% | — |
Clinical seizures | 20% | 1. Developmental delay (DD) and intellectual disability (ID). All known individuals with SAS have some degree of developmental delay, often with intellectual disability of variable severity (mild to profound).; Speech/language. |
Source: GeneReviews — "SATB2-Associated Syndrome"
AND
Source: GeneReviews — "SATB2-Associated Syndrome"
In early infancy SATB2-associated syndrome (SAS) can be particularly difficult to diagnose when developmental delay, hypotonia, feeding difficulties, and palatal issues are the only observable features. During infancy and early childhood, many children with SAS are tested for Angelman syndrome and related disorders. Over time, the emergence of dental issues and distinctive behavioral issues along with lack of speech progression should lead clinicians to consider the diagnosis of SAS. Other syndromes that include developmental delay and dental abnormalities, such as KBG syndrome, can also be considered.
Table 3.
Disorders to Consider in the Differential Diagnosis of SATB2-Associated Syndrome
Source: GeneReviews — "SATB2-Associated Syndrome"
Biomarker and diagnostic research for SATB2 associated disorder has been reported in the published literature.
To establish the extent of disease and needs in an individual diagnosed with SAS, the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended.
Table 4.
SATB2-Associated Syndrome: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| Measurement of weight, length/height, growth velocity, head circumference | • To evaluate for poor growth
SAS-specific growth charts are available.1
| Neurologic eval | • Consider head MRI to evaluate for brain malformations if clinical seizures are present.2
Baseline EEG, preferably incl sleep stages to evaluate for ESES3
| Developmental assessment | • To incl motor, adaptive, cognitive, speech-language eval
Eval for early intervention/ special education
Neurobehavioral/
| Neuropsychiatric eval | For persons age 12 mos: screening for concerns incl sleep disturbances, ADHD, anxiety, /or findings suggestive of ASD
| Assess for palatal anomalies. | Referr...
Source: GeneReviews — "SATB2-Associated Syndrome"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "SATB2-Associated Syndrome"
View trials for SATB2 associated disorder
Evaluation |
|---|
Frequency |
|---|
ENT/Mouth | Eval by dentist/orthodontist | At least annually Neurologic |
Eyes | Eval by ophthalmologist | Annually or as clinically indicated |
Respiratory | Assess for signs/symptoms of sleep disturbance. | At each visit |
Source: GeneReviews — "SATB2-Associated Syndrome"
Estimated prevalence: 1-9 in 100,000 (Uncommon).
15 |
24% |
Research summaries | 10 | 16% |
Disease patterns and progression | 7 | 11% |
Testing and diagnosis research | 5 | 8% |
Clinical study results | 1 | 2% |
New treatment approaches | 1 | 2% |
Sun Y (2026). [PMID: 41939465](https://pubmed.ncbi.nlm.nih.gov/41939465/). *Front Oncol*. [Case Report / Case Series]
Gaasterland CMW (2026). [PMID: 41722828](https://pubmed.ncbi.nlm.nih.gov/41722828/). *J Clin Epidemiol*. [Review / Meta-Analysis]
Yaprak Bayrak B (2026). [PMID: 41870326](https://pubmed.ncbi.nlm.nih.gov/41870326/). *Int J Surg Pathol*. [Diagnostic / Biomarker]
Brünger T (2026). [PMID: 41822692](https://pubmed.ncbi.nlm.nih.gov/41822692/). *medRxiv*. [Case Report / Case Series]
Fazekas F (2026). [PMID: 41489603](https://pubmed.ncbi.nlm.nih.gov/41489603/). *Epilepsia*. [Case Report / Case Series]
Yi S (2026). [PMID: 41579226](https://pubmed.ncbi.nlm.nih.gov/41579226/). *Biochem Genet*. [Basic Science / Preclinical]
Shalaby A (2026). [PMID: 41857476](https://pubmed.ncbi.nlm.nih.gov/41857476/). *Clin Transl Oncol*. [Basic Science / Preclinical]
Harrison R (2026). [PMID: 41939296](https://pubmed.ncbi.nlm.nih.gov/41939296/). *Front Health Serv*. [Basic Science / Preclinical]
Ahn DG (2026). [PMID: 41705239](https://pubmed.ncbi.nlm.nih.gov/41705239/). *Front Immunol*. [Case Report / Case Series]
den Hoed J (2026). [PMID: 41139958](https://pubmed.ncbi.nlm.nih.gov/41139958/). *HGG Adv*. [Basic Science / Preclinical]